Artia Global Partners »

Nuvalent Inc-a shares owned by Artia Global Partners

Quarter-by-quarter ownership of Nuvalent Inc-a (NUVL) shares owned by Artia Global Partners from 13F filings

Historical chart of Artia Global Partners investment in Nuvalent Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Nuvalent Inc-a held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nuvalent Inc-a by Artia Global Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $1.6M 15k 102.30

More positions owned by Artia Global Partners

Eli Lilly & Co. (LLY)
Novo-nordisk A S Adr (NVO)
Viking Therapeutics (VKTX)
Intra Cellular Therapies (ITCI)
Astrazeneca Sponsored Adr (AZN)
Soleno Therapeutics (SLNO)
Alnylam Pharmaceuticals (ALNY)
Vertex Pharmaceuticals Incorporated (VRTX)
Vaxcyte (PCVX)
Argenx Se Sponsored Adr (ARGX)
Axsome Therapeutics (AXSM)
Protagonist Therapeutics (PTGX)
Neurocrine Biosciences (NBIX)
Revolution Medicines (RVMD)
Dyne Therapeutics (DYN)

View all positions for Artia Global Partners

Top funds holding Nuvalent Inc-a

Deerfield Management Company
Paradigm Biocapital Advisors
Vanguard Group
BlackRock
BlackRock
Perceptive Advisors
Bain Capital Life Sciences Investors
Fairmount Funds Management
State Street Corporation
Woodline Partners
Boxer Capital
T. Rowe Price Associates
Commodore Capital
Driehaus Capital Management
Geode Capital Management

View all funds holding Nuvalent Inc-a